Showing results (11-20 of 142) with videos related to

Sort By:
Pageof 15
Japanese Journal of Radiology|November 30, 2010
Intestinal metastasis from non-small-cell lung cancer initially detected by ¹⁸F-fluorodeoxyglucose positron emission tomographyHiroaki Akamatsu, Asuka Tsuya, Kyoichi Kaira, et al.
Translational Lung Cancer Research|December 13, 2024
Invasive mucinous adenocarcinoma harbored MET exon 14 skipping mutation: case reportAtsushi Washioka, Hiroaki Akamatsu, Takeya Sugimoto, et al.
Japanese Journal of Clinical Oncology|April 16, 2013
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405)Hiroaki Akamatsu, Akira Inoue, Tetsuya Mitsudomi, et al.
Lung Cancer (Amsterdam, Netherlands)|January 16, 2019
The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancerKentaro Ito, Satoru Miura, Tadashi Sakaguchi, et al.
Clinical Lung Cancer|September 11, 2018
Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib StudyHiroaki Akamatsu, Yasuhiro Koh, Yuichi Ozawa, et al.
Nihon Kokyuki Gakkai Zasshi = the Journal of the Japanese Respiratory Society|August 15, 2008
[A case of pulmonary amebiasis]Hiroaki Akamatsu, Takashi Ueji, Mio Hayakawa, et al.
Medical Mycology Journal|September 19, 2014
Cryptococcus gattii genotype VGIIb infection in JapanIchiro Kawamura, Katsuhiko Kamei, Kyoko Yarita, et al.
Clinical Lung Cancer|August 31, 2019
Subgroup Analysis of Japanese Patients in a Phase III Study of Atezolizumab in Extensive-stage Small-cell Lung Cancer (IMpower133)Makoto Nishio, Shunichi Sugawara, Shinji Atagi, et al.
BMC Cancer|February 8, 2020
Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapyNahomi Tokudome, Yasuhiro Koh, Hiroaki Akamatsu, et al.
Therapeutic Advances in Medical Oncology|February 22, 2021
A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study)Ryota Shibaki, Hiroaki Akamatsu, Terufumi Kato, et al.
Pageof 15